Abstract
There is a clinical need to identify biomarkers able to select patients who are most likely to develop aggressive/complicated disease and early select them for appropriate therapy. Changes in the glycosylation profile of intestinal lymphocytic infiltrate was previously demonstrated to regulate T cell activity being associated with disease severity in ulcerative colitis (UC) patients. We interrogated whether this heterogeneous expression of branched N-glycans on intestinal inflammatory infiltrate predict therapy response early in disease course. The expression levels of the branched N-glycans in colonic biopsies collected around time of diagnosis from a well-characterized cohort of 131 UC patients were correlated with response to standard therapy. ROC analysis and specificity/sensitivity were determined. Branched N-glycans levels around time of diagnosis predict non-response to conventional therapy with 75% of specificity. Moreover, high levels of branched N-glycans predict 78% of UC patients that will display a favorable disease course (exclusively under 5-ASA therapy with more than 5 years the disease). The best predictive performance was observed in severe UC patients with Mayo endoscopic subsore 3 and in those that were naïve for therapy. Multivariable analysis revealed that low levels of branched N-glycans and high levels of C Reactive Protein (CRP) around time of diagnosis act as independent predictors of non-response to standard therapy. A powerful effect of the combined use of the branched N-glycans and CRP was observed. Our results reveal a potential (glyco)biomarker that predicts, early in the disease course, patients that will fail to respond to standard therapy, benefiting thereby from other therapeutic strategies as biologics.
Funding Information
  • FCT-Fundação para a Ciência e Tecnologia
  • Norte Portugal Regional Programme
  • European Regional Development Fund (NORTE-01-0145-FEDER-000029)